|
1
|
Aarsland D, Marsh L and Schrag A:
Neuropsychiatric symptoms in Parkinson's disease. Mov Disord.
24:2175–2186. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hely MA, Reid WG, Adena MA, Halliday GM
and Morris JG: The Sydney multicenter study of Parkinson's disease:
The inevitability of dementia at 20 years. Mov Disord. 23:837–844.
2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Emre M, Aarsland D, Albanese A, Byrne EJ,
Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A,
et al: Rivastigmine for dementia associated with Parkinson's
disease. N Engl J Med. 351:2509–2518. 2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kehagia AA, Barker RA and Robbins TW:
Cognitive impairment in Parkinson's disease: The dual syndrome
hypothesis. Neurodegener Dis. 11:79–92. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mattay VS, Tessitore A, Callicott JH,
Bertolino A, Goldberg TE, Chase TN, Hyde TM and Weinberger DR:
Dopaminergic modulation of cortical function in patients with
Parkinson's disease. Ann Neurol. 51:156–164. 2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Olanow CW, Schapira AH and Roth T: Waking
up to sleep episodes in Parkinson's disease. Mov Disord.
15:212–215. 2000.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Louter M, Munneke M, Bloem BR and Overeem
S: Nocturnal hypokinesia and sleep quality in Parkinson's disease.
J Am Geriatr Soc. 60:1104–1108. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pfeiffer RF: Autonomic Dysfunction in
Parkinson's disease. Neurotherapeutics. 17:1464–1479.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhou Z, Zhou X, Zhou X, Xiang Y, Zhu L,
Qin L, Qin L, Wang Y, Pan H, Zhao Y, et al: Characteristics of
Autonomic Dysfunction in Parkinson's disease: A large chinese
multicenter cohort study. Front Aging Neurosci.
13(761044)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Blackett H, Walker R and Wood B: Urinary
dysfunction in Parkinson's disease: A review. Park Relat Disord.
15:81–87. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sakakibara R, Tateno F, Kishi M, Tsuyuzaki
Y, Uchiyama T and Yamamoto T: Pathophysiology of bladder
dysfunction in Parkinson's disease. Neurobiol Dis. 46:565–571.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sakakibara R, Uchiyama T, Yamanishi T,
Shirai K and Hattori T: Bladder and bowel dysfunction in
Parkinson's disease. J Neural Transm (Vienna). 115:443–460.
2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sakakibara R, Shinotoh H, Uchiyama T,
Yoshiyama M, Hattori T and Yamanishi T: SPECT imaging of the
dopamine transporter with [(123)I]-beta-CIT reveals marked decline
of nigrostriatal dopaminergic function in Parkinson's disease with
urinary dysfunction. J Neurol Sci. 187:55–59. 2001.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Winge K, Friberg L, Werdelin L, Nielsen KK
and Stimpel H: Relationship between nigrostriatal dopaminergic
degeneration, urinary symptoms, and bladder control in Parkinson's
disease. Eur J Neurol. 12:842–850. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fasano A, Visanji NP, Liu LW, Lang AE and
Pfeiffer RF: Gastrointestinal dysfunction in Parkinson's disease.
Lancet Neurol. 14:625–639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Abbott RD, Petrovitch H, White LR, Masaki
KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS and
Ross GW: Frequency of bowel movements and the future risk of
Parkinson's disease. Neurology. 57:456–462. 2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Goldstein DS, Holmes C, Li ST, Bruce S,
Metman LV and Cannon RO III: Cardiac sympathetic denervation in
Parkinson disease. Ann Intern Med. 133:338–347. 2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Goldstein DS: Orthostatic hypotension as
an early finding in Parkinson's disease. Clin Auton Res. 16:46–54.
2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fanciulli A, Strano S, Colosimo C,
Caltagirone C, Spalletta G and Pontieri FE: The potential
prognostic role of cardiovascular autonomic failure in
α-synucleinopathies. Eur J Neurol. 20:231–235. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Snider SR, Fahn S, Isgreen WP and Cote LJ:
Primary sensory symptoms in parkinsonism. Neurology. 26:423–429.
1976.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Goetz CG, Tanner CM, Levy M, Wilson RS and
Garron DC: Pain in Parkinson's disease. Mov Disord. 1:45–49.
1986.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Waseem S and Gwinn-Hardy K: Pain in
Parkinson's disease. Common yet seldom recognized symptom is
treatable. Postgrad Med. 110:33–34. 2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Nagy A, Eordegh G, Paroczy Z, Markus Z and
Benedek G: Multisensory integration in the basal ganglia. Eur J
Neurosci. 24:917–924. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Takakusaki K, Oohinata-Sugimoto J, Saitoh
K and Habaguchi T: Role of basal ganglia-brainstem systems in the
control of postural muscle tone and locomotion. Prog Brain Res.
143:231–237. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
von Coelln R and Shulman LM: Clinical
subtypes and genetic heterogeneity: Of lumping and splitting in
Parkinson disease. Curr Opin Neurol. 29:727–734. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Braak H, Ghebremedhin E, Rub U, Bratzke H
and Del Tredici K: Stages in the development of Parkinson's
disease-related pathology. Cell Tissue Res. 318:121–134.
2004.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen Z, Li G and Liu J: Autonomic
dysfunction in Parkinson's disease: Implications for
pathophysiology, diagnosis, and treatment. Neurobiol Dis.
134(104700)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jankovic J, Gilden JL, Hiner BC, Kaufmann
H, Brown DC, Coghlan CH, Rubin M and Fouad-Tarazi FM: Neurogenic
orthostatic hypotension: A double-blind, placebo-controlled study
with midodrine. Am J Med. 95:38–48. 1993.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kehagia AA, Barker RA and Robbins TW:
Neuropsychological and clinical heterogeneity of cognitive
impairment and dementia in patients with Parkinson's disease.
Lancet Neurol. 9:1200–1213. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Rissardo JP and Caprara ALF: Risk factors
for Parkinson's disease dementia. Ann Mov Disord. 6:156–159.
2023.
|
|
31
|
Udow SJ, Robertson AD, MacIntosh BJ, Espay
AJ, Rowe JB, Lang AE and Masellis M: Under pressure. Is There a
Link between Orthostatic hypotension and cognitive impairment in
α-Synucleinopathies. J Neurol Neurosurg Psychiatry. 87:1311–1321.
2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lahrmann H, Cortelli P, Hilz M, Mathias
CJ, Struhal W and Tassinari M: EFNS guidelines on the diagnosis and
management of Orthostatic hypotension. Eur J Neurol. 13:930–936.
2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Freeman R, Wieling W, Axelrod FB, Benditt
DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P,
Gibbons CH, et al: Consensus statement on the definition of
Orthostatic hypotension, neurally mediated syncope and the postural
tachycardia syndrome. Clin Auton Res. 21:69–72. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Rascol O, Perez-Lloret S, Damier P, Delval
A, Derkinderen P, Destee A, Meissner WG, Tison F and Negre-Pages L:
Falls in ambulatory non-demented patients with Parkinson's disease.
J Neural Transm(Vienna). 122:1447–1455. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Verbaan D, Marinus J, Visser M, van Rooden
SM, Stiggelbout AM, Middelkoop HA and van Hilten JJ: Cognitive
impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry.
78:1182–1187. 2007.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Martinez-Martin P, Schapira AH, Stocchi F,
Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, et
al: Prevalence of nonmotor symptoms in Parkinson's disease in an
international setting; study using nonmotor symptoms questionnaire
in 545 patients. Mov Disord. 22:1623–1629. 2007.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Cutsforth-Gregory JK and Low PA:
Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer.
Neurol Ther. 8:307–324. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Pitton Rissardo J and Fornari Caprara AL:
Parkinson's disease rating scales: A literature review. Ann Mov
Disord. 3:3–22. 2020.
|
|
39
|
Goldstein DS, Pechnik S, Holmes C, Eldadah
B and Sharabi Y: Association between supine hypertension and
Orthostatic Hypotension in autonomic failure. Hypertension.
42:136–142. 2003.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Vagaonescu TD, Saadia D, Tuhrim S,
Phillips RA and Kaufmann H: Hypertensive cardiovascular damage in
patients with primary autonomic failure. Lancet. 355:725–726.
2000.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Garland EM, Gamboa A, Okamoto L, Raj SR,
Black BK, Davis TL, Biaggioni I and Robertson D: Renal impairment
of pure autonomic failure. Hypertension. 54:1057–1061.
2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Minhas JS, Wang X, Lavados PM, Moullaali
TJ, Arima H, Billot L, Hackett ML, Olavarria VV, Middleton S,
Pontes-Neto O, et al: Blood pressure variability and outcome in
acute ischemic and hemorrhagic stroke: A post hoc analysis of the
HeadPoST study. J Hum Hypertens. 33:411–418. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pickering TG, Hall JE, Appel LJ, Falkner
BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG and Roccella EJ:
Subcommittee of Professional and Public Education of the American
Heart Association Council on High Blood Pressure Research.
Recommendations for blood pressure measurement in humans and
experimental animals: Part 1: blood pressure measurement in humans:
a statement for professionals from the Subcommittee of Professional
and Public Education of the American Heart Association Council on
High Blood pressure Research. Hypertension. 45:142–161.
2005.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Mancia G, De Backer G, Dominiczak A,
Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE,
Laurent S, et al: 2007 Guidelines for the management of arterial
hypertension: The Task Force for the Management of Arterial
Hypertension of the European Society of Hypertension (ESH) and of
the European Society of Cardiology (ESC). Eur Heart J.
28:1462–1536. 2007.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ogihara T, Kikuchi K, Matsuoka H, Fujita
T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, et al:
The Japanese Society of Hypertension Guidelines for the Management
of Hypertension (JSH 2009). Hypertens Res. 32:3–107.
2009.PubMed/NCBI
|
|
46
|
Verdecchia P, Angeli F, Borgioni C,
Gattobigio R and Reboldi G: Ambulatory blood pressure and
cardiovascular outcome in relation to perceived sleep deprivation.
Hypertension. 49:777–783. 2007.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Henskens LH, van Boxtel MP, Kroon AA, van
Oostenbrugge RJ, Lodder J and de Leeuw PW: Subjective sleep
disturbance increases the nocturnal blood pressure level and
attenuates the correlation with target-organ damage. J Hypertens.
29:242–250. 2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Clement DL, De Buyzere ML, De Bacquer DA,
de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun
JJ, Six RO, et al: Office versus Ambulatory Pressure Study
Investigators. Prognostic value of ambulatory blood-pressure
recordings in patients with treated hypertension. N Engl J Med.
348:2407–2415. 2003.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Dolan E, Stanton A, Thijs L, Hinedi K,
Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA and
O'Brien E: Superiority of ambulatory over clinic blood pressure
measurement in predicting mortality: The Dublin outcome study.
Hypertension. 46:156–161. 2005.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sega R, Facchetti R, Bombelli M, Cesana G,
Corrao G, Grassi G and Mancia G: Prognostic value of ambulatory and
home blood pressure compared with office blood pressure in the
general population: follow-up results from the Pressioni Arteriose
Monitorate e Loro Associazioni (PAMELA) study. Circulation.
111:1777–1783. 2005.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler
J, Ben-Arie L and Bursztyn M: Predictors of all-cause mortality in
clinical ambulatory monitoring: Unique aspects of blood pressure
during sleep. Hypertension. 49:1235–1241. 2007.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Boggia J, Li Y, Thijs L, Hansen TW, Kikuya
M, Bjorklund-Bodegard K, Richart T, Ohkubo T, Kuznetsova T,
Torp-Pedersen C, et al: Prognostic accuracy of day versus night
ambulatory blood pressure: A cohort study. Lancet. 370:1219–1229.
2007.PubMed/NCBI View Article : Google Scholar
|
|
53
|
O'Brien E, Sheridan J and O'Malley K:
Dippers and non-dippers. Lancet. 2(397)1988.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Verdecchia P, Schillaci G, Guerrieri M,
Gatteschi C, Benemio G, Boldrini F and Porcellati C: Circadian
blood pressure changes and left ventricular hypertrophy in
essential hypertension. Circulation. 81:528–536. 1990.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Shimada K, Kawamoto A, Matsubayashi K,
Nishinaga M, Kimura S and Ozawa T: Diurnal blood pressure
variations and silent cerebrovascular damage in elderly patients
with hypertension. J Hypertens. 10:875–878. 1992.PubMed/NCBI
|
|
56
|
Kario K, Matsuo T, Kobayashi H, Imiya M,
Matsuo M and Shimada K: Nocturnal fall of blood pressure and silent
cerebrovascular damage in elderly hypertensive patients. Advanced
silent cerebrovascular damage in extreme dippers. Hypertension.
27:130–135. 1996.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Umehara T, Toyoda C and Oka H:
Postprandial hypotension in de novo Parkinson's disease: A
comparison with orthostatic hypotension. Parkinsonism Relat Disord.
20:573–577. 2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Jansen RW and Lipsitz LA: Postprandial
hypotension: Epidemiology, pathophysiology, and clinical
management. Ann Intern Med. 122:286–295. 1995.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Thomaides T, Bleasdale-Barr K, Chaudhuri
KR, Pavitt D, Marsden CD and Mathias CJ: Cardiovascular and
hormonal responses to liquid food challenge in idiopathic
Parkinson's disease multiple system atrophy, and pure autonomic
failure. Neurology. 43:900–904. 1993.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Awosika A, Adabanya U, Millis RM, Omole AE
and Moon JH: Postprandial Hypotension: An underreported silent
killer in the aged. Cureus. 15(e35411)2023.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Low DA, da Nobrega AC and Mathias CJ:
Exercise-induced hypotension in autonomic disorders. Auton
Neurosci. 171:66–78. 2012.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Groom D: Cardiovascular observations on
Tarahumara Indian runners-the modern Spartans. Am Heart J.
81:304–314. 1971.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Smith GD and Mathias CJ: Postural
hypotension enhanced by exercise in patients with chronic autonomic
failure. QJM. 88:251–256. 1995.PubMed/NCBI
|
|
64
|
Kenney MJ and Seals DR: Postexercise
hypotension. Key features, mechanisms, and clinical significance.
Hypertension. 22:653–664. 1993.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Polito MD and Farinatti PT: The effects of
muscle mass and number of sets during resistance exercise on
postexercise hypotension. J Strength Cond Res. 23:2351–2357.
2009.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Chamsi-Pasha MA and Chamsi-Pasha H:
Avicenna's contribution to cardiology. Avicenna J Med. 4:9–12.
2014.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Nauman J, Janszky I, Vatten LJ and Wisloff
U: Temporal changes in resting heart rate and deaths from ischemic
heart disease. JAMA. 306:2579–2587. 2011.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Cole CR, Blackstone EH, Pashkow FJ, Snader
CE and Lauer MS: Heart-rate recovery immediately after exercise as
a predictor of mortality. N Engl J Med. 341:1351–1357.
1999.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Martin CE, Shaver JA, Leon DF, Thompson
ME, Reddy PS and Leonard JJ: Autonomic mechanisms in hemodynamic
responses to isometric exercise. J Clin Invest. 54:104–115.
1974.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Smith LL, Kukielka M and Billman GE: Heart
rate recovery after exercise: A predictor of ventricular
fibrillation susceptibility after myocardial infarction. Am J
Physiol Heart Circ Physiol. 288:H1763–H1769. 2005.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Hemingway H, Shipley M, Brunner E, Britton
A, Malik M and Marmot M: Does autonomic function link social
position to coronary risk? The Whitehall II study. Circulation.
111:3071–3077. 2005.PubMed/NCBI View Article : Google Scholar
|
|
72
|
La Rovere MT, Pinna GD, Maestri R, Mortara
A, Capomolla S, Febo O, Ferrari R, Franchini M, Gnemmi M, Opasich
C, et al: Short-term heart rate variability strongly predicts
sudden cardiac death in chronic heart failure patients.
Circulation. 107:565–570. 2003.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Maetzler W, Liepelt I and Berg D:
Progression of Parkinson's disease in the clinical phase: Potential
markers. Lancet Neurol. 8:1158–1171. 2009.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Miyagi T, Yamazato M, Nakamura T,
Tokashiki T, Namihira Y, Kokuba K, Ishihara S, Sakima H and Ohya Y:
Power spectral analysis of heart rate variability is useful as a
screening tool for detecting sympathetic and parasympathetic
nervous dysfunctions in Parkinson's disease. BMC Neurol.
22(339)2022.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Bidikar MP, Jagtap GJ and Chakor RT:
Influence of deep breathing on heart rate variability in
Parkinson's disease: Co-relation with severity of disease and
non-motor symptom scale score. J Clin Diagn Res. 8:BC01–BC03.
2014.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Kim JB, Phillips Z, Paik SH, Kang SY, Jeon
NJ, Kim BJ and Kim BM: Cerebral hemodynamic monitoring of
Parkinson's disease patients with orthostatic intolerance during
head-up tilt test. Neurophotonics. 7(025002)2020.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Schmidt C, Herting B, Prieur S, Junghanns
S, Schweitzer K, Globas C, Schöls L, Reichmann H, Berg D and
Ziemssen T: Valsalva manoeuvre in patients with different
Parkinsonian disorders. J Neural Transm (Vienna). 116:875–880.
2009.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Huang CC, Lai YR, Lien CY, Cheng BC, Kung
CT, Chiang YF and Lu CH: Effectiveness of different methods for
baroreflex sensitivity assessment in determining the severity of
cardiovascular autonomic neuropathy in patients With Parkinson's
disease. Front Neurosci. 16(833344)2022.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Puisieux F, Bulckaen H, Fauchais AL,
Drumez S, Salomez-Granier F and Dewailly P: Ambulatory blood
pressure monitoring and postprandial hypotension in elderly persons
with falls or syncopes. J Gerontol A Biol Sci Med Sci.
55:M535–M540. 2000.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Shen L, Yang X, Lu W, Chen W, Ye X and Wu
D: 24-hour ambulatory blood pressure alterations in patients with
Parkinson's disease. Brain Behav. 12(e2428)2022.PubMed/NCBI View Article : Google Scholar
|
|
81
|
DiFrancisco-Donoghue J, Elokda A, Lamberg
EM, Bono N and Werner WG: Norepinephrine and cardiovascular
responses to maximal exercise in Parkinson's disease on and off
medication. Mov Disord. 24:1773–1778. 2009.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Cohn JN: Plasma norepinephrine and
mortality. Clin Cardiol. 18 (3 Suppl I):I9–I12. 1995.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Bristow MR: Beta-adrenergic receptor
blockade in chronic heart failure. Circulation. 101:558–569.
2000.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Rowell LB, Johnson DG, Chase PB, Comess KA
and Seals DR: Hypoxemia raises muscle sympathetic activity but not
norepinephrine in resting humans. J Appl Physiol (1985).
66:1736–1743. 1989.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Akaogi Y, Asahina M, Yamanaka Y, Koyama Y
and Hattori T: Sudomotor, skin vasomotor, and cardiovascular
reflexes in 3 clinical forms of Lewy body disease. Neurology.
73:59–65. 2009.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Asahina M, Sakakibara R, Liu Z, Ito T,
Yamanaka Y, Nakazawa K, Shimizu E and Hattori T: The raphe
magnus/pallidus regulates sweat secretion and skin vasodilation of
the cat forepaw pad: A preliminary electrical stimulation study.
Neurosci Lett. 415:283–287. 2007.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Antonio-Rubio I, Madrid-Navarro CJ,
Salazar-Lopez E, Perez-Navarro MJ, Saez-Zea C, Gomez-Milan E,
Mínguez-Castellanos A and Escamilla-Sevilla F: Abnormal
thermography in Parkinson's disease. Park Relat Disord. 21:852–857.
2015.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Orimo S, Oka T, Miura H, Tsuchiya K, Mori
F, Wakabayashi K, Nagao T and Yokochi M: Sympathetic cardiac
denervation in Parkinson's disease and pure autonomic failure but
not in multiple system atrophy. J Neurol Neurosurg Psychiatry.
73:776–777. 2002.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Pitton Rissardo J and Fornari Caprara AL:
Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in
Parkinson's disease: A comprehensive review. Brain Sci.
13(1471)2023.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Courbon F, Brefel-Courbon C, Thalamas C,
Alibelli MJ, Berry I, Montastruc JL, Rascol O and Senard JM:
Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac
sympathetic denervation in Parkinson's disease. Mov Disord.
18:890–897. 2003.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Kim JS, Park HE, Oh YS, Lee SH, Park JW,
Son BC and Lee KS: Orthostatic hypotension and cardiac sympathetic
denervation in Parkinson disease patients with REM sleep behavioral
disorder. J Neurol Sci. 362:59–63. 2016.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Yoshita M, Hayashi M and Hirai S:
Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine
in Parkinson's disease. Nucl Med Commun. 19:137–142.
1998.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Amino T, Orimo S, Itoh Y, Takahashi A,
Uchihara T and Mizusawa H: Profound cardiac sympathetic denervation
occurs in Parkinson disease. Brain Pathol. 15:29–34.
2005.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Orimo S, Ozawa E, Oka T, Nakade S,
Tsuchiya K, Yoshimoto M, Wakabayashi K and Takahashi H: Different
histopathology accounting for a decrease in myocardial MIBG uptake
in PD and MSA. Neurology. 57:1140–1141. 2001.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Bonuccelli U, Lucetti C, Del Dotto P,
Ceravolo R, Gambaccini G, Bernardini S, Rossi G and Piaggesi A:
Orthostatic hypotension in de novo Parkinson disease. Arch Neurol.
60:1400–1404. 2003.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Ejaz AA, Sekhon IS and Munjal S:
Characteristic findings on 24-h ambulatory blood pressure
monitoring in a series of patients with Parkinson's disease. Eur J
Intern Med. 17:417–420. 2006.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Kaufmann H and Goldstein DS: Autonomic
dysfunction in Parkinson disease. Handb Clin Neurol. 117:259–278.
2013.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Gibbons CH and Freeman R: Clinical
implications of delayed orthostatic hypotension: A 10-year
follow-up study. Neurology. 85:1362–1367. 2015.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Jamnadas-Khoda J, Koshy S, Mathias CJ,
Muthane UB, Ragothaman M and Dodaballapur SK: Are current
recommendations to diagnose orthostatic hypotension in Parkinson's
disease satisfactory? Mov Disord. 24:1747–1751. 2009.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Aarsland D, Andersen K, Larsen JP, Lolk A
and Kragh-Sorensen P: Prevalence and characteristics of dementia in
Parkinson disease: An 8-year prospective study. Arch Neurol.
60:387–392. 2003.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Merola A, Romagnolo A, Rosso M, Suri R,
Berndt Z, Maule S, Lopiano L and Espay AJ: Autonomic dysfunction in
Parkinson's disease: A prospective cohort study. Mov Disord.
33:391–397. 2018.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Longardner K, Bayram E and Litvan I:
Orthostatic hypotension is associated with cognitive decline in
Parkinson disease. Front Neurol. 11(897)2020.PubMed/NCBI View Article : Google Scholar
|
|
103
|
McDonald C, Newton JL and Burn DJ:
Orthostatic hypotension and cognitive impairment in Parkinson's
disease: Causation or association? Mov Disord. 31:937–946.
2016.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Palma JA and Kaufmann H: Treatment of
autonomic dysfunction in Parkinson disease and other
synucleinopathies. Mov Disord. 33:372–390. 2018.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Anang JB, Nomura T, Romenets SR, Nakashima
K, Gagnon JF and Postuma RB: Dementia Predictors in Parkinson
Disease: A validation study. J Parkinsons Dis. 7:159–162.
2017.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Cicero CE, Raciti L, Monastero R, Mostile
G, Donzuso G, Sciacca G, Luca A, Terravecchia C, Giuliano L, Baschi
R, et al: Cardiovascular autonomic function and MCI in Parkinson's
disease. Parkinsonism Relat Disord. 69:55–58. 2019.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Centi J, Freeman R, Gibbons CH, Neargarder
S, Canova AO and Cronin-Golomb A: Effects of Orthostatic
hypotension on cognition in Parkinson disease. Neurology. 88:17–24.
2017.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Sforza M, Assogna F, Rinaldi D, Sette G,
Tagliente S and Pontieri FE: Orthostatic hypotension acutely
impairs executive functions in Parkinson's disease. Neurol Sci.
39:1459–1462. 2018.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Peralta C, Stampfer-Kountchev M, Karner E,
Kollensperger M, Geser F, Wolf E, Seppi K, Benke T, Poewe W and
Wenning GK: Orthostatic hypotension and attention in Parkinson's
disease with and without dementia. J Neural Transm (Vienna).
114:585–588. 2007.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Fanciulli A, Gobel G, Ndayisaba JP,
Granata R, Duerr S, Strano S, Colosimo C, Poewe W, Pontieri FE and
Wenning GK: Supine hypertension in Parkinson's disease and multiple
system atrophy. Clin Auton Res. 26:97–105. 2016.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Jordan J and Biaggioni I: Diagnosis and
treatment of Supine hypertension in autonomic failure patients with
orthostatic hypotension. J Clin Hypertens Greenwich. 4:139–145.
2002.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Chobanian AV, Bakris GL, Black HR, Cushman
WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright
JT Jr, et al: The Seventh Report of the Joint National Committee on
prevention, detection, evaluation, and treatment of high blood
pressure: The JNC 7 report. JAMA. 289:2560–2572. 2003.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Kim JS, Oh YS, Lee KS, Kim YI, Yang DW and
Goldstein DS: Association of cognitive dysfunction with
neurocirculatory abnormalities in early Parkinson disease.
Neurology. 79:1323–1331. 2012.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Schmidt C, Berg D, Herting Prieur S,
Junghanns S, Schweitzer K, Globas C, Schöls L, Reichmann H and
Ziemssen T: Loss of nocturnal blood pressure fall in various
extrapyramidal syndromes. Mov Disord. 24:2136–2142. 2009.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Sommer S, Aral-Becher B and Jost W:
Nondipping in blood pressure. Park Dis. 2011(897586)2011.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Fanciulli A, Jordan J, Biaggioni I,
Calandra-Buonaura G, Cheshire WP, Cortelli P, Eschlboeck S, Grassi
G, Hilz MJ, Kaufmann H, et al: Consensus statement on the
definition of neurogenic SH in cardiovascular autonomic failure by
the American Autonomic Society (AAS) and the European Federation of
Autonomic Societies (EFAS) : Endorsed by the European Academy of
Neurology (EAN) and the European Society of Hypertension (ESH).
Clin Auton Res. 28:355–362. 2018.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Umehara T, Matsuno H, Toyoda C and Oka H:
Clinical characteristics of Supine hypertension in de novo
Parkinson disease. Clin Auton Res. 26:15–21. 2016.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Palma JA, Redel-Traub G, Porciuncula A,
Samaniego-Toro D, Millar Vernetti P, Lui YW, Norcliffe-Kaufmann L
and Kaufmann H: The impact of Supine hypertension on target organ
damage and survival in patients with synucleinopathies and
neurogenic orthostatic hypotension. Park Relat Disord. 75:97–104.
2020.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Tanaka R, Shimo Y, Yamashiro K, Ogawa T,
Nishioka K, Oyama G, Umemura A and Hattori N: Association between
abnormal nocturnal blood pressure profile and dementia in
Parkinson's disease. Parkinsonism Relat Disord. 46:24–29.
2018.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Oh YS, Kim JS, Yang DW, Koo JS, Kim YI,
Jung HO and Lee KS: Nighttime blood pressure and white matter
hyperintensities in patients with Parkinson disease. Chronobiol
Int. 30:811–817. 2013.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Sunwoo MK, Jeon S, Ham JH, Hong JY, Lee
JE, Lee JM, Sohn YH and Lee PH: The burden of white matter
hyperintensities is a predictor of progressive mild cognitive
impairment in patients with Parkinson's disease. Eur J Neurol.
21:922–e50. 2014.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Oka H, Umehara T, Nakahara A and Matsuno
H: Comparisons of cardiovascular dysautonomia and cognitive
impairment between de novo Parkinson's disease and de novo dementia
with Lewy bodies. BMC Neurol. 20(350)2020.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Fengler S, Liepelt-Scarfone I, Brockmann
K, Schaffer E, Berg D and Kalbe E: Cognitive changes in prodromal
Parkinson's disease: A review. Mov Disord. 32:1655–1666.
2017.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Perez F, Helmer C, Foubert-Samier A,
Auriacombe S, Dartigues JF and Tison F: Risk of dementia in an
elderly population of Parkinson's disease patients: A 15-year
population-based study. Alzheimers Dement. 8:463–469.
2012.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Aarsland D, Andersen K, Larsen JP, Lolk A,
Nielsen H and Kragh-Sorensen P: Risk of dementia in Parkinson's
disease: A community-based, prospective study. Neurology.
56:730–736. 2001.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Aarsland D, Zaccai J and Brayne C: A
systematic review of prevalence studies of dementia in Parkinson's
disease. Mov Disord. 20:1255–1263. 2005.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Aarsland D, Larsen JP, Tandberg E and
Laake K: Predictors of nursing home placement in Parkinson's
disease: A population-based, prospective study. J Am Geriatr Soc.
48:938–942. 2000.PubMed/NCBI View Article : Google Scholar
|
|
128
|
McKeith IG, Ferman TJ, Thomas AJ, Blanc F,
Boeve BF, Fujishiro H, Kantarci K, Muscio C, O'Brien JT, Postuma
RB, et al: Research criteria for the diagnosis of prodromal
dementia with Lewy bodies. Neurology. 94:743–755. 2020.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Aarsland D, Bronnick K, Williams-Gray C,
Weintraub D, Marder K, Kulisevsky J, Burn D and Barone P: Mild
cognitive impairment in Parkinson disease: A multicenter pooled
analysis. Neurology. 75:1062–1069. 2010.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Lawson RA, Yarnall AJ, Duncan GW, Breen
DP, Khoo TK, Williams-Gray CH, Barker RA and Burn DJ: ICICLE-PD
study group. Stability of mild cognitive impairment in newly
diagnosed Parkinson's disease. J Neurol Neurosurg Psychiatry.
88:648–652. 2017.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Domellof ME, Ekman U, Forsgren L and Elgh
E: Cognitive function in the early phase of Parkinson's disease, a
five-year follow-up. Acta Neurol Scand. 132:79–88. 2015.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Weintraub D, Simuni T, Caspell-Garcia C,
Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P and Burn D:
Cognitive performance and neuropsychiatric symptoms in early,
untreated Parkinson's disease. Mov Disord. 30:919–927.
2015.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Pedersen KF, Larsen JP, Tysnes OB and
Alves G: Natural course of mild cognitive impairment in Parkinson
disease: A 5-year population-based study. Neurology. 88:767–774.
2017.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Jones JD, Kuhn TP and Szymkowicz SM:
Reverters from PD-MCI to cognitively intact are at risk for future
cognitive impairment: Analysis of the PPMI cohort. Parkinsonism
Relat Disord. 47:3–7. 2018.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Erro R, Santangelo G, Barone P, Picillo M,
Amboni M, Longo K, Giordano F, Moccia M, Allocca R, Pellecchia MT
and Vitale C: Do subjective memory complaints herald the onset of
mild cognitive impairment in Parkinson disease? J Geriatr
Psychiatry Neurol. 27:276–281. 2014.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Purri R, Brennan L, Rick J, Xie SX, Deck
BL, Chahine LM, Dahodwala N, Chen-Plotkin A, Duda JE, Morley JF, et
al: Subjective Cognitive Complaint in Parkinson's disease patients
with normal cognition: Canary in the coal mine? Mov Disord.
35:1618–1625. 2020.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Chua CY, Koh MRE, Chia NS, Ng SY, Saffari
SE, Wen MC, Chen RY, Choi X, Heng DL, Neo SX, et al: Subjective
cognitive Complaints in early Parkinson's disease patients with
normal cognition are associated with affective symptoms.
Parkinsonism Relat Disord. 82:24–28. 2021.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Szewczyk-Krolikowski K, Tomlinson P, Nithi
K, Wade-Martins R, Talbot K, Ben-Shlomo Y and Hu MT: The influence
of age and gender on motor and non-motor features of early
Parkinson's disease: Initial findings from the Oxford Parkinson
Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord.
20:99–105. 2014.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Augustine EF, Perez A, Dhall R, Umeh CC,
Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, et
al: Sex differences in clinical features of early, treated
Parkinson's disease. PLoS One. 10(e0133002)2015.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Gao L, Nie K, Tang H, Wang L, Zhao J, Gan
R, Huang J, Feng S, Zhu R, Duan Z, et al: Sex differences in
cognition among Chinese people with Parkinson's disease. J Clin
Neurosci. 22:488–492. 2015.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Liu R, Umbach DM, Peddada SD, Xu Z,
Troster AI, Huang X and Chen H: Potential sex differences in
nonmotor symptoms in early drug-naive Parkinson disease. Neurology.
84:2107–2115. 2015.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Sundermann EE, Maki PM, Rubin LH, Lipton
RB, Landau S and Biegon A: Alzheimer's Disease Neuroimaging
Initiative. Female advantage in verbal memory: Evidence of
sex-specific cognitive reserve. Neurology. 87:1916–1924.
2016.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Gonzalez-Latapi P, Bayram E, Litvan I and
Marras C: Cognitive Impairment in Parkinson's disease:
Epidemiology, clinical profile, protective and risk factors. Behav
Sci (Basel). 11(74)2021.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Compta Y, Valente T, Saura J, Segura B,
Iranzo A, Serradell M, Junqué C, Tolosa E, Valldeoriola F, Muñoz E,
et al: Correlates of cerebrospinal fluid levels of oligomeric- and
total-α-synuclein in premotor, motor and dementia stages of
Parkinson's disease. J Neurol. 262:294–306. 2015.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Stewart T, Liu C, Ginghina C, Cain KC,
Auinger P, Cholerton B, Shi M and Zhang J: Parkinson Study Group
DATATOP Investigators. Cerebrospinal fluid α-synuclein predicts
cognitive decline in Parkinson disease progression in the DATATOP
cohort. Am J Pathol. 184:966–975. 2014.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Hansson O, Hall S, Ohrfelt A, Zetterberg
H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK,
et al: Levels of cerebrospinal fluid α-synuclein oligomers are
increased in Parkinson's disease with dementia and dementia with
Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther.
6(25)2014.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Coughlin DG, Hurtig HI and Irwin DJ:
Pathological influences on clinical heterogeneity in lewy body
diseases. Mov Disord. 35:5–19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Robinson JL, Lee EB, Xie SX, Rennert L,
Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, et
al: Neurodegenerative disease concomitant proteinopathies are
prevalent, age-related and APOE4-associated. Brain. 141:2181–2193.
2018.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Smith C, Malek N, Grosset K, Cullen B,
Gentleman S and Grosset DG: Neuropathology of dementia in patients
with Parkinson's disease: A systematic review of autopsy studies. J
Neurol Neurosurg Psychiatry. 90:1234–1243. 2019.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Mollenhauer B, Trenkwalder C, von Ahsen N,
Bibl M, Steinacker P, Brechlin P, Schindehuette J, Poser S,
Wiltfang J and Otto M: Beta-amlyoid 1-42 and tau-protein in
cerebrospinal fluid of patients with Parkinson's disease dementia.
Dement Geriatr Cogn Disord. 22:200–208. 2006.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Compta Y, Pereira JB, Rios J,
Ibarretxe-Bilbao N, Junque C, Bargallo N, Cámara A, Buongiorno M,
Fernández M, Pont-Sunyer C and Martí MJ: Combined dementia-risk
biomarkers in Parkinson's disease: A prospective longitudinal
study. Parkinsonism Relat Disord. 19:717–724. 2013.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Howlett DR, Whitfield D, Johnson M, Attems
J, O'Brien JT, Aarsland D, Lai MK, Lee JH, Chen C, Ballard C, et
al: Regional multiple pathology scores are associated with
cognitive decline in lewy body dementias. Brain Pathol. 25:401–408.
2015.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Jellinger KA and Attems J: Cerebral
amyloid angiopathy in Lewy body disease. J Neural Transm (Vienna).
115:473–482. 2008.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Hansen D, Ling H, Lashley T, Foley JA,
Strand C, Eid TM, Holton JL and Warner TT: Novel
clinicopathological characteristics differentiate dementia with
Lewy bodies from Parkinson's disease dementia. Neuropathol Appl
Neurobiol. 47:143–156. 2021.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Chahine LM, Xie SX, Simuni T, Tran B,
Postuma R, Amara A, Oertel WH, Iranzo A, Scordia C, Fullard M, et
al: Longitudinal changes in cognition in early Parkinson's disease
patients with REM sleep behavior disorder. Parkinsonism Relat
Disord. 27:102–106. 2016.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Forbes E, Tropea TF, Mantri S, Xie SX and
Morley JF: Modifiable comorbidities associated with cognitive
decline in Parkinson's disease. Mov Disord Clin Pract. 8:254–263.
2021.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Guo Y, Xu W, Liu FT, Li JQ, Cao XP, Tan L,
Wang J and Yu JT: Modifiable risk factors for cognitive impairment
in Parkinson's disease: A systematic review and meta-analysis of
prospective cohort studies. Mov Disord. 34:876–883. 2019.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Kivipelto M, Ngandu T, Laatikainen T,
Winblad B, Soininen H and Tuomilehto J: Risk score for the
prediction of dementia risk in 20 years among middle aged people: A
longitudinal, population-based study. Lancet Neurol. 5:735–741.
2006.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Chahine LM, Dos Santos C, Fullard M,
Scordia C, Weintraub D, Erus G, Rosenthal L, Davatzikos C and
McMillan CT: Modifiable vascular risk factors, white matter disease
and cognition in early Parkinson's disease. Eur J Neurol.
26:246–e18. 2019.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Dong C, Nabizadeh N, Caunca M, Cheung YK,
Rundek T, Elkind MS, DeCarli C, Sacco RL, Stern Y and Wright CB:
Cognitive correlates of white matter lesion load and brain atrophy:
The Northern Manhattan Study. Neurology. 85:441–449.
2015.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Erten-Lyons D, Woltjer R, Kaye J, Mattek
N, Dodge HH, Green S, Tran H, Howieson DB, Wild K and Silbert LC:
Neuropathologic basis of white matter hyperintensity accumulation
with advanced age. Neurology. 81:977–983. 2013.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Mollenhauer B, Zimmermann J, Sixel-Doring
F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T
and Trenkwalder C: DeNoPa Study Group. Baseline predictors for
progression 4 years after Parkinson's disease diagnosis in the De
Novo Parkinson Cohort (DeNoPa). Mov Disord. 34:67–77.
2019.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Kim HJ, Oh ES, Lee JH, Moon JS, Oh JE,
Shin JW, Lee KJ, Baek IC, Jeong SH, Song HJ, et al: Relationship
between changes of body mass index (BMI) and cognitive decline in
Parkinson's disease (PD). Arch Gerontol Geriatr. 55:70–72.
2012.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Yoo HS, Chung SJ, Lee PH, Sohn YH and Kang
SY: The influence of body mass index at diagnosis on cognitive
decline in Parkinson's disease. J Clin Neurol. 15:517–526.
2019.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Anang JB, Gagnon JF, Bertrand JA, Romenets
SR, Latreille V, Panisset M, Montplaisir J and Postuma RB:
Predictors of dementia in Parkinson disease: A prospective cohort
study. Neurology. 83:1253–1260. 2014.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Goldstein DS, Holmes CS, Dendi R, Bruce SR
and Li ST: Orthostatic hypotension from sympathetic denervation in
Parkinson's disease. Neurology. 58:1247–1255. 2002.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Papapetropoulos S, Gonzalez J and Mash DC:
The effect of ischemic cerebrovascular disease on the clinical
characteristics of Parkinson's disease. A post-mortem study. Eur J
Neurol. 13:96–97. 2006.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Moran LB and Graeber MB: Towards a pathway
definition of Parkinson's disease: A complex disorder with links to
cancer, diabetes and inflammation. Neurogenetics. 9:1–13.
2008.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Menon R and Farina C: Shared molecular and
functional frameworks among five complex human disorders: A
comparative study on interactomes linked to susceptibility genes.
PLoS One. 6(e18660)2011.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Cheong JLY, de Pablo-Fernandez E, Foltynie
T and Noyce AJ: The association between type 2 diabetes mellitus
and Parkinson's disease. J Parkinsons Dis. 10:775–789.
2020.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Santiago JA and Potashkin JA: Shared
dysregulated pathways lead to Parkinson's disease and diabetes.
Trends Mol Med. 19:176–186. 2013.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Bosco D, Plastino M, Cristiano D, Colica
C, Ermio C, De Bartolo M, Mungari P, Fonte G, Consoli D, Consoli A
and Fava A: Dementia is associated with insulin resistance in
patients with Parkinson's disease. J Neurol Sci. 315:39–43.
2012.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Shen C, Guo Y, Luo W, Lin C and Ding M:
Serum urate and the risk of Parkinson's disease: Results from a
meta-analysis. Can J Neurol Sci. 40:73–79. 2013.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Weisskopf MG, O'Reilly E, Chen H,
Schwarzschild MA and Ascherio A: Plasma urate and risk of
Parkinson's disease. Am J Epidemiol. 166:561–567. 2007.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Jain S, Ton TG, Boudreau RM, Yang M,
Thacker EL, Studenski S, Longstreth WT Jr, Strotmeyer ES and Newman
AB: The risk of Parkinson disease associated with urate in a
community-based cohort of older adults. Neuroepidemiology.
36:223–229. 2011.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Rissardo JP and Caprara ALF: Uric acid and
Parkinson's disease. Menoufia Med J. 35:2093–2094. 2023.
|
|
177
|
Maetzler W, Stapf AK, Schulte C, Hauser
AK, Lerche S, Wurster I, Schleicher E, Melms A and Berg D: Serum
and cerebrospinal fluid uric acid levels in lewy body disorders:
associations with disease occurrence and amyloid-β pathway. J
Alzheimers Dis. 27:119–126. 2011.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Annanmaki T, Pessala-Driver A, Hokkanen L
and Murros K: Uric acid associates with cognition in Parkinson's
disease. Parkinsonism Relat Disord. 14:576–578. 2008.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Moccia M, Picillo M, Erro R, Vitale C,
Longo K, Amboni M, Santangelo G, Spina E, De Rosa A, De Michele G,
et al: Is serum uric acid related to non-motor symptoms in de-novo
Parkinson's disease patients? Parkinsonism Relat Disord.
20:772–775. 2014.PubMed/NCBI View Article : Google Scholar
|
|
180
|
Moccia M, Picillo M, Erro R, Vitale C,
Longo K, Amboni M, Santangelo G, Palladino R, Capo G, Orefice G, et
al: Presence and progression of non-motor symptoms in relation to
uric acid in de novo Parkinson's disease. Eur J Neurol. 22:93–98.
2015.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Block ML and Hong JS: Microglia and
inflammation-mediated neurodegeneration: Multiple triggers with a
common mechanism. Prog Neurobiol. 76:77–98. 2005.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Fan Z, Aman Y, Ahmed I, Chetelat G,
Landeau B, Ray Chaudhuri K, Brooks DJ and Edison P: Influence of
microglial activation on neuronal function in Alzheimer's and
Parkinson's disease dementia. Alzheimers Dement. 11:608–621.e7.
2015.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Aviles-Olmos I, Limousin P, Lees A and
Foltynie T: Parkinson's disease, insulin resistance and novel
agents of neuroprotection. Brain. 136(Pt 2):374–384.
2013.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Garabadu D, Agrawal N, Sharma A and Sharma
S: Mitochondrial metabolism: A common link between
neuroinflammation and neurodegeneration. Behav Pharmacol.
30:642–652. 2019.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Jeon YM, Kwon Y, Jo M, Lee S, Kim S and
Kim HJ: The Role Glial Mitochondria in α-Synuclein Toxicity. Front
Cell Dev Biol. 8(548283)2020.PubMed/NCBI View Article : Google Scholar
|
|
186
|
Gatt AP, Duncan OF, Attems J, Francis PT,
Ballard CG and Bateman JM: Dementia in Parkinson's disease is
associated with enhanced mitochondrial complex I deficiency. Mov
Disord. 31:352–359. 2016.PubMed/NCBI View Article : Google Scholar
|
|
187
|
Toklu HZ and Tumer N: Oxidative Stress,
Brain Edema, Blood-Brain Barrier Permeability, and Autonomic
Dysfunction from Traumatic Brain Injury. In: Brain Neurotrauma:
Molecular, Neuropsychological, and Rehabilitation Aspects. Kobeissy
FH (Ed.). Chapter 5. CRC Press/Taylor & Francis, Boca Raton Fl,
2015.
|
|
188
|
Krauss JK: Movement disorders secondary to
craniocerebral trauma. Handb Clin Neurol. 128:475–496.
2015.PubMed/NCBI View Article : Google Scholar
|
|
189
|
Schiehser DM, Filoteo JV, Litvan I,
Pirogovsky-Turk E, Lessig SL and Song DS: Cognitive functioning in
individuals with Parkinson's disease and traumatic brain injury: A
longitudinal study. Parkinsonism Relat Disord. 30:58–61.
2016.PubMed/NCBI View Article : Google Scholar
|
|
190
|
Nombela C, Rowe JB, Winder-Rhodes SE,
Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ,
Firbank MJ, et al: Genetic impact on cognition and brain function
in newly diagnosed Parkinson's disease: ICICLE-PD Study. Brain.
137(Pt 10):2743–2758. 2014.PubMed/NCBI View Article : Google Scholar
|
|
191
|
Paul KC, Rausch R, Creek MM, Sinsheimer
JS, Bronstein JM, Bordelon Y and Ritz B: APOE, MAPT, and COMT and
Parkinson's disease susceptibility and cognitive symptom
progression. J Park Dis. 6:349–359. 2016.PubMed/NCBI View Article : Google Scholar
|
|
192
|
Williams-Gray CH, Goris A, Saiki M,
Foltynie T, Compston DA, Sawcer SJ and Barker RA: Apolipoprotein E
genotype as a risk factor for susceptibility to and dementia in
Parkinson's disease. J Neurol. 256:493–498. 2009.PubMed/NCBI View Article : Google Scholar
|
|
193
|
Williams-Gray CH, Mason SL, Evans JR,
Foltynie T, Brayne C, Robbins TW and Barker RA: The CamPaIGN study
of Parkinson's disease: 10-year outlook in an incident
population-based cohort. J Neurol Neurosurg Psychiatry.
84:1258–1264. 2013.PubMed/NCBI View Article : Google Scholar
|
|
194
|
Harward SC, Hedrick NG, Hall CE,
Parra-Bueno P, Milner TA, Pan E, Laviv T, Hempstead BL, Yasuda R
and McNamara JO: Autocrine BDNF-TrkB signalling within a single
dendritic spine. Nature. 538:99–103. 2016.PubMed/NCBI View Article : Google Scholar
|
|
195
|
Chen ZY, Patel PD, Sant G, Meng CX, Teng
KK, Hempstead BL and Lee FS: Variant brain-derived neurotrophic
factor (BDNF) (Met66) alters the intracellular trafficking and
activity-dependent secretion of wild-type BDNF in neurosecretory
cells and cortical neurons. J Neurosci. 24:4401–4411.
2004.PubMed/NCBI View Article : Google Scholar
|
|
196
|
Guerini FR, Beghi E, Riboldazzi G,
Zangaglia R, Pianezzola C, Bono G, Casali C, Di Lorenzo C, Agliardi
C, Nappi G, et al: BDNF Val66Met polymorphism is associated with
cognitive impairment in Italian patients with Parkinson's disease.
Eur J Neurol. 16:1240–1245. 2009.PubMed/NCBI View Article : Google Scholar
|
|
197
|
Karakasis C, Kalinderi K, Katsarou Z,
Fidani L and Bostantjopoulou S: Association of brain-derived
neurotrophic factor (BDNF) Val66Met polymorphism with Parkinson's
disease in a Greek population. J Clin Neurosci. 18:1744–1745.
2011.PubMed/NCBI View Article : Google Scholar
|
|
198
|
The CA, Lee TS, Kuchibhatla M, Ashley-Koch
A, Macfall J, Krishnan R and Beyer J: Bipolar disorder,
brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and
brain morphology. PLoS One. 7(e38469)2012.PubMed/NCBI View Article : Google Scholar
|
|
199
|
Svetel M, Pekmezovic T, Markovic V,
Novakovic I, Dobricic V, Djuric G, Stefanova E and Kostić V: No
association between brain-derived neurotrophic factor G196A
polymorphism and clinical features of Parkinson's disease. Eur
Neurol. 70:257–262. 2013.PubMed/NCBI View Article : Google Scholar
|
|
200
|
Poewe W, Seppi K, Tanner CM, Halliday GM,
Brundin P, Volkmann J, Schrag AE and Lang AE: Parkinson disease.
Nat Rev Primer. 3(17013)2017.PubMed/NCBI View Article : Google Scholar
|
|
201
|
Bridi JC and Hirth F: Mechanisms of
α-Synuclein Induced Synaptopathy in Parkinson's disease. Front
Neurosci. 12(80)2018.PubMed/NCBI View Article : Google Scholar
|
|
202
|
Aarsland D, Batzu L, Halliday GM, Geurtsen
GJ, Ballard C, Ray Chaudhuri K and Weintraub D: Parkinson
disease-associated cognitive impairment. Nat Rev Primer.
7(47)2021.PubMed/NCBI View Article : Google Scholar
|
|
203
|
Sasikumar S and Strafella AP: Imaging Mild
Cognitive Impairment and Dementia in Parkinson's disease. Front
Neurol. 11(47)2020.PubMed/NCBI View Article : Google Scholar
|
|
204
|
Ranganath A and Jacob SN: Doping the Mind:
Dopaminergic modulation of prefrontal cortical cognition.
Neuroscientist. 22:593–603. 2016.PubMed/NCBI View Article : Google Scholar
|
|
205
|
Westbrook A, van den Bosch R, Maatta JI,
Hofmans L, Papadopetraki D, Cools R and Frank MJ: Dopamine promotes
cognitive effort by biasing the benefits versus costs of cognitive
work. Science. 367:1362–1366. 2020.PubMed/NCBI View Article : Google Scholar
|
|
206
|
Keren NI, Taheri S, Vazey EM, Morgan PS,
Granholm AC, Aston-Jones GS and Eckert MA: Histologic validation of
locus coeruleus MRI contrast in post-mortem tissue. Neuroimage.
113:235–245. 2015.PubMed/NCBI View Article : Google Scholar
|
|
207
|
Borodovitsyna O, Flamini M and Chandler D:
Noradrenergic modulation of cognition in health and disease. Neural
Plast. 2017(6031478)2017.PubMed/NCBI View Article : Google Scholar
|
|
208
|
Ehrminger M, Latimier A, Pyatigorskaya N,
Garcia-Lorenzo D, Leu-Semenescu S, Vidailhet M, Lehericy S and
Arnulf I: The coeruleus/subcoeruleus complex in idiopathic rapid
eye movement sleep behaviour disorder. Brain. 139(Pt 4):1180–1188.
2016.PubMed/NCBI View Article : Google Scholar
|
|
209
|
Sommerauer M, Fedorova TD, Hansen AK,
Knudsen K, Otto M, Jeppesen J, Frederiksen Y and Blicher JU:
Evaluation of the noradrenergic system in Parkinson's disease: An
11C-MeNER PET and neuromelanin MRI study. Brain. 141:496–504.
2018.PubMed/NCBI View Article : Google Scholar
|
|
210
|
Sinn DI and Gibbons CH: Pathophysiology
and Treatment of Orthostatic Hypotension in Parkinsonian Disorders.
Curr Treat Options Neurol. 18(28)2016.PubMed/NCBI View Article : Google Scholar
|
|
211
|
Zhan Y, Raza MU, Yuan L and Zhu MY:
Critical Role of Oxidatively Damaged DNA in Selective Noradrenergic
Vulnerability. Neuroscience. 422:184–201. 2019.PubMed/NCBI View Article : Google Scholar
|
|
212
|
Buddhala C, Loftin SK, Kuley BM, Cairns
NJ, Campbell MC, Perlmutter JS and Kotzbauer PT: Dopaminergic,
serotonergic, and noradrenergic deficits in Parkinson disease. Ann
Clin Transl Neurol. 2:949–959. 2015.PubMed/NCBI View Article : Google Scholar
|
|
213
|
Betts MJ, Kirilina E, Otaduy MCG, Ivanov
D, Acosta-Cabronero J, Callaghan MF, Lambert C, Cardenas-Blanco A,
Pine K, Passamonti L, et al: Locus coeruleus imaging as a biomarker
for noradrenergic dysfunction in neurodegenerative diseases. Brain.
142:2558–2571. 2019.PubMed/NCBI View Article : Google Scholar
|
|
214
|
Schulz J, Pagano G, Fernandez Bonfante JA,
Wilson H and Politis M: Nucleus basalis of Meynert degeneration
precedes and predicts cognitive impairment in Parkinson's disease.
Brain. 141:1501–1516. 2018.PubMed/NCBI View Article : Google Scholar
|
|
215
|
Bohnen NI, Albin RL, Muller ML, Petrou M,
Kotagal V, Koeppe RA, Scott PJ and Frey KA: Frequency of
cholinergic and caudate nucleus dopaminergic deficits across the
predemented cognitive spectrum of Parkinson disease and evidence of
interaction effects. JAMA Neurol. 72:194–200. 2015.PubMed/NCBI View Article : Google Scholar
|
|
216
|
Pereira JB, Hall S, Jalakas M, Grothe MJ,
Strandberg O, Stomrud E, Westman E, van Westen D and Hansson O:
Longitudinal degeneration of the basal forebrain predicts
subsequent dementia in Parkinson's disease. Neurobiol Dis.
139(104831)2020.PubMed/NCBI View Article : Google Scholar
|
|
217
|
Ballinger EC, Ananth M, Talmage DA and
Role LW: Basal forebrain cholinergic circuits and signaling in
cognition and cognitive decline. Neuron. 91:1199–1218.
2016.PubMed/NCBI View Article : Google Scholar
|
|
218
|
Pillet LE, Taccola C, Cotoni J, Thiriez H,
Andre K and Verpillot R: Correction: Correlation between cognition
and plasma noradrenaline level in Alzheimer's disease: A potential
new blood marker of disease evolution. Transl Psychiatry.
10(409)2020.PubMed/NCBI View Article : Google Scholar
|
|
219
|
Alexandris AS, Walker L, Liu AKL, McAleese
KE, Johnson M, Pearce RKB, Gentleman SM and Attems J: Cholinergic
deficits and galaninergic hyperinnervation of the nucleus basalis
of Meynert in Alzheimer's disease and Lewy body disorders.
Neuropathol Appl Neurobiol. 46:264–278. 2020.PubMed/NCBI View Article : Google Scholar
|
|
220
|
Mattila PM, Roytta M, Lonnberg P,
Marjamaki P, Helenius H and Rinne JO: Choline acetytransferase
activity and striatal dopamine receptors in Parkinson's disease in
relation to cognitive impairment. Acta Neuropathol. 102:160–166.
2001.PubMed/NCBI View Article : Google Scholar
|
|
221
|
Gaykema RP and Zaborszky L: Direct
catecholaminergic-cholinergic interactions in the basal forebrain.
II. Substantia nigra-ventral tegmental area projections to
cholinergic neurons. J Comp Neurol. 374:555–577. 1996.PubMed/NCBI View Article : Google Scholar
|
|
222
|
Gargouri F, Gallea C, Mongin M,
Pyatigorskaya N, Valabregue R, Ewenczyk C, Sarazin M, Yahia-Cherif
L, Vidailhet M and Lehéricy S: Multimodal magnetic resonance
imaging investigation of basal forebrain damage and cognitive
deficits in Parkinson's disease. Mov Disord. 34:516–525.
2019.PubMed/NCBI View Article : Google Scholar
|
|
223
|
Hall H, Reyes S, Landeck N, Bye C, Leanza
G, Double K, Thompson L, Halliday G and Kirik D: Hippocampal Lewy
pathology and cholinergic dysfunction are associated with dementia
in Parkinson's disease. Brain. 137(Pt 9):2493–2508. 2014.PubMed/NCBI View Article : Google Scholar
|
|
224
|
Liu AKL, Chau TW, Lim EJ, Ahmed I, Chang
RC, Kalaitzakis ME, Graeber MB, Gentleman SM and Pearce RKB:
Hippocampal CA2 Lewy pathology is associated with cholinergic
degeneration in Parkinson's disease with cognitive decline. Acta
Neuropathol Commun. 7(61)2019.PubMed/NCBI View Article : Google Scholar
|
|
225
|
Nicastro N, Garibotto V and Burkhard PR:
Extrastriatal 123I-FP-CIT SPECT impairment in
Parkinson's disease - the PPMI cohort. BMC Neurol.
20(192)2020.PubMed/NCBI View Article : Google Scholar
|
|
226
|
Qamhawi Z, Towey D, Shah B, Pagano G,
Seibyl J, Marek K, Borghammer P, Brooks DJ and Pavese N: Clinical
correlates of raphe serotonergic dysfunction in early Parkinson's
disease. Brain. 138 (Pt 10):2964–2973. 2015.PubMed/NCBI View Article : Google Scholar
|
|
227
|
Maillet A, Krack P, Lhommee E, Metereau E,
Klinger H, Favre E, Le Bars D, Schmitt E, Bichon A, Pelissier P, et
al: The prominent role of serotonergic degeneration in apathy,
anxiety and depression in de novo Parkinson's disease. Brain. 139
(Pt 9):2486–2502. 2016.PubMed/NCBI View Article : Google Scholar
|
|
228
|
Smith CR, Cullen B, Sheridan MP, Cavanagh
J, Grosset KA and Grosset DG: Cognitive impairment in Parkinson's
disease is multifactorial: A neuropsychological study. Acta Neurol
Scand. 141:500–508. 2020.PubMed/NCBI View Article : Google Scholar
|
|
229
|
Amin J, Holmes C, Dorey RB, Tommasino E,
Casal YR, Williams DM, Dupuy C, Nicoll JAR and Boche D:
Neuroinflammation in dementia with Lewy bodies: A human post-mortem
study. Transl Psychiatry. 10(267)2020.PubMed/NCBI View Article : Google Scholar
|
|
230
|
Devanand DP, Pradhaban G, Liu X, Khandji
A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R,
et al: Hippocampal and entorhinal atrophy in mild cognitive
impairment: Prediction of Alzheimer disease. Neurology. 68:828–836.
2007.PubMed/NCBI View Article : Google Scholar
|
|
231
|
Harding AJ and Halliday GM: Cortical Lewy
body pathology in the diagnosis of dementia. Acta Neuropathol.
102:355–363. 2001.PubMed/NCBI View Article : Google Scholar
|
|
232
|
Schaser AJ, Osterberg VR, Dent SE,
Stackhouse TL, Wakeham CM, Boutros SW, Weston LJ, Owen N, Weissman
TA, Luna E, et al: Alpha-synuclein is a DNA binding protein that
modulates DNA repair with implications for Lewy body disorders. Sci
Rep. 9(10919)2019.PubMed/NCBI View Article : Google Scholar
|
|
233
|
Petrou M, Dwamena BA, Foerster BR,
MacEachern MP, Bohnen NI, Muller ML, Albin RL and Frey KA: Amyloid
deposition in Parkinson's disease and cognitive impairment: A
systematic review. Mov Disord. 30:928–935. 2015.PubMed/NCBI View Article : Google Scholar
|
|
234
|
Reimand J, Boon BDC, Collij LE, Teunissen
CE, Rozemuller AJM, van Berckel BNM, Scheltens P, Ossenkoppele R
and Bouwman F: Amyloid-β PET and CSF in an autopsy-confirmed
cohort. Ann Clin Transl Neurol. 7:2150–2160. 2020.PubMed/NCBI View Article : Google Scholar
|
|
235
|
Toledo JB, Gopal P, Raible K, Irwin DJ,
Brettschneider J, Sedor S, Waits K, Boluda S, Grossman M, Van
Deerlin VM, et al: Pathological ?-synuclein distribution in
subjects with coincident Alzheimer's and Lewy body pathology. Acta
Neuropathol. 131:393–409. 2016.PubMed/NCBI View Article : Google Scholar
|
|
236
|
Howard E, Irwin DJ, Rascovsky K, Nevler N,
Shellikeri S, Tropea TF, Spindler M, Deik A, Chen-Plotkin A,
Siderowf A, et al: Cognitive Profile and Markers of Alzheimer
disease-type pathology in patients with lewy body dementias.
Neurology. 96:e1855–e1864. 2021.PubMed/NCBI View Article : Google Scholar
|
|
237
|
Tan MMX, Lawton MA, Jabbari E, Reynolds
RH, Iwaki H, Blauwendraat C, Kanavou S, Pollard MI, Hubbard L,
Malek N, et al: Genome-Wide Association Studies of Cognitive and
Motor Progression in Parkinson's disease. Mov Disord. 36:424–433.
2021.PubMed/NCBI View Article : Google Scholar
|
|
238
|
Hopfner F, Mueller SH, Szymczak S, Junge
O, Tittmann L, May S, Lohmann K, Grallert H, Lieb W, Strauch K, et
al: Rare variants in specific lysosomal genes are associated with
Parkinson's disease. Mov Disord. 35:1245–1248. 2020.PubMed/NCBI View Article : Google Scholar
|
|
239
|
Setó-Salvia N, Pagonabarraga J, Houlden H,
Pascual-Sedano B, Dols-Icardo O, Tucci A, Paisán-Ruiz C, Campolongo
A, Antón-Aguirre S, Martín I, et al: Glucocerebrosidase mutations
confer a greater risk of dementia during Parkinson's disease
course. Mov Disord. 27:393–399. 2012.PubMed/NCBI View Article : Google Scholar
|
|
240
|
Chia R, Sabir MS, Bandres-Ciga S,
Saez-Atienzar S, Reynolds RH, Gustavsson E, Walton RL, Ahmed S,
Viollet C, Ding J, et al: Genome sequencing analysis identifies new
loci associated with Lewy body dementia and provides insights into
its genetic architecture. Nat Genet. 53:294–303. 2021.PubMed/NCBI View Article : Google Scholar
|
|
241
|
Jiang Z, Huang Y, Zhang P, Han C, Lu Y, Mo
Z, Zhang Z, Li X, Zhao S, Cai F, et al: Characterization of a
pathogenic variant in GBA for Parkinson's disease with mild
cognitive impairment patients. Mol Brain. 13(102)2020.PubMed/NCBI View Article : Google Scholar
|
|
242
|
Martelle SE, Raffield LM, Palmer ND, Cox
AJ, Freedman BI, Hugenschmidt CE, Williamson JD and Bowden DW:
Dopamine pathway gene variants may modulate cognitive performance
in the DHS-Mind Study. Brain Behav. 6(e0044)2016.PubMed/NCBI View Article : Google Scholar
|
|
243
|
Bäckström D, Granåsen G, Domellöf ME,
Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K and
Forsgren L: Early predictors of mortality in parkinsonism and
Parkinson disease: A population-based study. Neurology.
91:e2045–e2056. 2018.PubMed/NCBI View Article : Google Scholar
|
|
244
|
Aarsland D, Perry R, Brown A, Larsen JP
and Ballard C: Neuropathology of dementia in Parkinson's disease: A
prospective, community-based study. Ann Neurol. 58:773–776.
2005.PubMed/NCBI View Article : Google Scholar
|
|
245
|
Colosimo C and Riario Sforza A: Diagnostic
imaging of degenerative diseases of the extrapyramidal system.
Radiol Med. 106 (3 Suppl 1):S19–S23. 2003.PubMed/NCBI(In Italian).
|
|
246
|
Wakabayashi K, Takahashi H, Takeda S,
Ohama E and Ikuta F: Parkinson's disease: The presence of Lewy
bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol.
76:217–221. 1988.PubMed/NCBI View Article : Google Scholar
|
|
247
|
Braak H, Del Tredici K, Rub U, de Vos RA,
Jansen Steur EN and Braak E: Staging of brain pathology related to
sporadic Parkinson's disease. Neurobiol Aging. 24:197–211.
2003.PubMed/NCBI View Article : Google Scholar
|
|
248
|
Kosaka K: Diffuse Lewy body disease in
Japan. J Neurol. 237:197–204. 1990.PubMed/NCBI View Article : Google Scholar
|
|
249
|
Gibb WR: Idiopathic Parkinson's disease
and the Lewy body disorders. Neuropathol Appl Neurobiol.
12:223–234. 1986.PubMed/NCBI View Article : Google Scholar
|
|
250
|
Braak H, Rub U, Jansen Steur EN, Del
Tredici K and de Vos RA: Cognitive status correlates with
neuropathologic stage in Parkinson disease. Neurology.
64:1404–1410. 2005.PubMed/NCBI View Article : Google Scholar
|
|
251
|
Horimoto Y, Matsumoto M, Akatsu H, Ikari
H, Kojima K, Yamamoto T, Otsuka Y, Ojika K, Ueda R and Kosaka K:
Autonomic dysfunctions in dementia with Lewy bodies. J Neurol.
250:530–533. 2003.PubMed/NCBI View Article : Google Scholar
|
|
252
|
Orimo S, Amino T, Itoh Y, Takahashi A,
Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K and Takahashi
H: Cardiac sympathetic denervation precedes neuronal loss in the
sympathetic ganglia in Lewy body disease. Acta Neuropathol.
109:583–588. 2005.PubMed/NCBI View Article : Google Scholar
|
|
253
|
Larner AJ, Mathias CJ and Rossor MN:
Autonomic failure preceding dementia with Lewy bodies. J Neurol.
247:229–231. 2000.PubMed/NCBI View Article : Google Scholar
|
|
254
|
Mehrabian S, Duron E, Labouree F, Rollot
F, Bune A, Traykov L and Hanon O: Relationship between orthostatic
hypotension and cognitive impairment in the elderly. J Neurol Sci.
299:45–48. 2010.PubMed/NCBI View Article : Google Scholar
|
|
255
|
Moretti R, Torre P, Antonello RM,
Manganaro D, Vilotti C and Pizzolato G: Risk factors for vascular
dementia: Hypotension as a key point. Vasc Health Risk Manag.
4:395–402. 2008.PubMed/NCBI View Article : Google Scholar
|
|
256
|
Coon EA, Cutsforth-Gregory JK and
Benarroch EE: Neuropathology of autonomic dysfunction in
synucleinopathies. Mov Disord. 33:349–358. 2018.PubMed/NCBI View Article : Google Scholar
|
|
257
|
De Pablo-Fernandez E, Courtney R, Warner
TT and Holton JL: A histologic study of the circadian system in
Parkinson disease, multiple system atrophy, and progressive
supranuclear Palsy. JAMA Neurol. 75:1008–1012. 2018.PubMed/NCBI View Article : Google Scholar
|
|
258
|
Sharabi Y and Goldstein DS: Mechanisms of
orthostatic hypotension and supine hypertension in Parkinson
disease. J Neurol Sci. 310:123–128. 2011.PubMed/NCBI View Article : Google Scholar
|
|
259
|
Treglia G, Cason E, Gabellini A, Giordano
A and Fagioli G: Recent developments in innervation imaging using
iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body
diseases. Neurol Sci. 31:417–422. 2010.PubMed/NCBI View Article : Google Scholar
|
|
260
|
Iwanaga K, Wakabayashi K, Yoshimoto M,
Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M and
Takahashi H: Lewy body-type degeneration in cardiac plexus in
Parkinson's and incidental Lewy body diseases. Neurology.
52:1269–1271. 1999.PubMed/NCBI View Article : Google Scholar
|
|
261
|
Goldstein DS, Eisenhofer G, Stull R, Folio
CJ, Keiser HR and Kopin IJ: Plasma dihydroxyphenylglycol and the
intraneuronal disposition of norepinephrine in humans. J Clin
Invest. 81:213–220. 1988.PubMed/NCBI View Article : Google Scholar
|
|
262
|
Gibbons CH, Schmidt P, Biaggioni I,
Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew
M, Low P, et al: The recommendations of a consensus panel for the
screening, diagnosis, and treatment of neurogenic orthostatic
hypotension and associated supine hypertension. J Neurol.
264:1567–1582. 2017.PubMed/NCBI View Article : Google Scholar
|
|
263
|
Tipre DN and Goldstein DS: Cardiac and
extracardiac sympathetic denervation in Parkinson's disease with
orthostatic hypotension and in pure autonomic failure. J Nucl Med.
46:1775–1781. 2005.PubMed/NCBI
|
|
264
|
Noack C, Schroeder C, Heusser K and Lipp
A: Cardiovascular effects of levodopa in Parkinson's disease.
Parkinsonism Relat Disord. 20:815–818. 2014.PubMed/NCBI View Article : Google Scholar
|
|
265
|
Hastings MH, Maywood ES and Brancaccio M:
Generation of circadian rhythms in the suprachiasmatic nucleus. Nat
Rev Neurosci. 19:453–469. 2018.PubMed/NCBI View Article : Google Scholar
|
|
266
|
Videnovic A, Noble C, Reid KJ, Peng J,
Turek FW, Marconi A, Rademaker AW, Simuni T, Zadikoff C and Zee PC:
Circadian melatonin rhythm and excessive daytime sleepiness in
Parkinson disease. JAMA Neurol. 71:463–469. 2014.PubMed/NCBI View Article : Google Scholar
|
|
267
|
Espay AJ, LeWitt PA and Kaufmann H:
Norepinephrine deficiency in Parkinson's disease: The case for
noradrenergic enhancement. Mov Disord. 29:1710–1719.
2014.PubMed/NCBI View Article : Google Scholar
|
|
268
|
Kato S, Oda M, Hayashi H, Shimizu T,
Hayashi M, Kawata A and Tanabe H: Decrease of medullary
catecholaminergic neurons in multiple system atrophy and
Parkinson's disease and their preservation in amyotrophic lateral
sclerosis. J Neurol Sci. 132:216–221. 1995.PubMed/NCBI View Article : Google Scholar
|
|
269
|
Dayan E, Sklerov M and Browner N:
Disrupted hypothalamic functional connectivity in patients with
Parkinson's disease and autonomic dysfunction. Neurology.
90:e2051–e2058. 2018.PubMed/NCBI View Article : Google Scholar
|
|
270
|
Papapetropoulos S and Mash DC: Insular
pathology in Parkinson's disease patients with orthostatic
hypotension. Parkinsonism Relat Disord. 13:308–311. 2007.PubMed/NCBI View Article : Google Scholar
|
|
271
|
McAleese KE, Alafuzoff I, Charidimou A, De
Reuck J, Grinberg LT, Hainsworth AH, Hortobagyi T, Ince P,
Jellinger K, Gao J, et al: Post-mortem assessment in vascular
dementia: Advances and aspirations. BMC Med. 14(129)2016.PubMed/NCBI View Article : Google Scholar
|
|
272
|
Prins ND and Scheltens P: White matter
hyperintensities, cognitive impairment and dementia: An update. Nat
Rev Neurol. 11:157–165. 2015.PubMed/NCBI View Article : Google Scholar
|
|
273
|
Dadar M, Maranzano J, Ducharme S and
Collins DL: Alzheimer's Disease Neuroimaging Initiative. White
matter in different regions evolves differently during progression
to dementia. Neurobiol Aging. 76:71–79. 2019.PubMed/NCBI View Article : Google Scholar
|
|
274
|
Gunning-Dixon FM and Raz N: The cognitive
correlates of white matter abnormalities in normal aging: A
quantitative review. Neuropsychology. 14:224–232. 2000.PubMed/NCBI View Article : Google Scholar
|
|
275
|
Bohnen NI and Albin RL: White matter
lesions in Parkinson disease. Nat Rev Neurol. 7:229–236.
2011.PubMed/NCBI View Article : Google Scholar
|
|
276
|
Lee SJ, Kim JS, Yoo JY, Song IU, Kim BS,
Jung SL, Yang DW, Kim YI, Jeong DS and Lee KS: Influence of white
matter hyperintensities on the cognition of patients with Parkinson
disease. Alzheimer Assoc Disord. 24:227–233. 2010.PubMed/NCBI View Article : Google Scholar
|
|
277
|
Chesebro AG, Melgarejo JD, Leendertz R,
Igwe KC, Lao PJ, Laing KK, Rizvi B, Budge M, Meier IB, Calmon G, et
al: White matter hyperintensities mediate the association of
nocturnal blood pressure with cognition. Neurology. 94:e1803–e1810.
2020.PubMed/NCBI View Article : Google Scholar
|
|
278
|
Li Q, Yang Y, Reis C, Tao T, Li W, Li X
and Zhang JH: Cerebral small vessel disease. Cell Transpl.
27:1711–1722. 2018.PubMed/NCBI View Article : Google Scholar
|
|
279
|
Iadecola C and Gottesman RF: Neurovascular
and cognitive dysfunction in hypertension. Circ Res. 124:1025–1044.
2019.PubMed/NCBI View Article : Google Scholar
|
|
280
|
Kaufmann H and Palma JA: White matter
hyperintensities in the Synucleinopathies: Orthostatic Hypotension,
Supine Hypertension, or Both? Mov Disord Clin Pract. 7:595–598.
2020.PubMed/NCBI View Article : Google Scholar
|
|
281
|
Palma JA and Kaufmann H: Epidemiology,
Diagnosis, and Management of Neurogenic Orthostatic Hypotension.
Mov Disord Clin Pract. 4:298–308. 2017.PubMed/NCBI View Article : Google Scholar
|
|
282
|
Biaggioni I, Robertson D, Krantz S, Jones
M and Haile V: The anemia of primary autonomic failure and its
reversal with recombinant erythropoietin. Ann Intern Med.
121:181–186. 1994.PubMed/NCBI View Article : Google Scholar
|
|
283
|
Perera R, Isola L and Kaufmann H: Effect
of recombinant erythropoietin on anemia and Orthostatic Hypotension
in primary autonomic failure. Clin Auton Res. 5:211–213.
1995.PubMed/NCBI View Article : Google Scholar
|
|
284
|
May M and Jordan J: The osmopressor
response to water drinking. Am J Physiol Regul Integr Comp Physiol.
300:R40–R46. 2011.PubMed/NCBI View Article : Google Scholar
|
|
285
|
Shibao C, Gamboa A, Diedrich A, Dossett C,
Choi L, Farley G and Biaggioni I: Acarbose, an alpha-glucosidase
inhibitor, attenuates postprandial hypotension in autonomic
failure. Hypertension. 50:54–61. 2007.PubMed/NCBI View Article : Google Scholar
|
|
286
|
Freeman R: Clinical practice. Neurogenic
orthostatic hypotension. N Engl J Med. 358:615–624. 2008.PubMed/NCBI View Article : Google Scholar
|
|
287
|
Low DA, Vichayanrat E, Iodice V and
Mathias CJ: Exercise hemodynamics in Parkinson's disease and
autonomic dysfunction. Parkinson's disease Relat Disord.
20:549–553. 2014.PubMed/NCBI View Article : Google Scholar
|
|
288
|
Kooner JS, Raimbach S, Watson L, Bannister
R, Peart S and Mathias CJ: Relationship between splanchnic
vasodilation and postprandial hypotension in patients with primary
autonomic failure. J Hypertens. (Suppl 7):S40–S41. 1989.PubMed/NCBI View Article : Google Scholar
|
|
289
|
Mata IF, Leverenz JB, Weintraub D,
Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes
SL, Factor SA, et al: APOE, MAPT, and SNCA genes and cognitive
performance in Parkinson disease. JAMA Neurol. 71:1405–1412.
2014.PubMed/NCBI View Article : Google Scholar
|
|
290
|
Krediet CT, van Lieshout JJ, Bogert LW,
Immink RV, Kim YS and Wieling W: Leg crossing improves orthostatic
tolerance in healthy subjects: A placebo-controlled crossover
study. Am J Physiol Heart Circ Physiol. 291:H1768–H1772.
2006.PubMed/NCBI View Article : Google Scholar
|
|
291
|
Logan A, Freeman J, Pooler J, Kent B, Gunn
H, Billings S, Cork E and Marsden J: Effectiveness of
non-pharmacological interventions to treat orthostatic hypotension
in elderly people and people with a neurological condition: A
systematic review. JBI Evid Synth. 18:2556–2617. 2020.PubMed/NCBI View Article : Google Scholar
|
|
292
|
Protheroe CL, Dikareva A, Menon C and
Claydon VE: Are compression stockings an effective treatment for
orthostatic presyncope? PLoS One. 6(e28193)2011.PubMed/NCBI View Article : Google Scholar
|
|
293
|
Fanciulli A, Leys F, Falup-Pecurariu C,
Thijs R and Wenning GK: Management of Orthostatic Hypotension in
Parkinson's Disease. J Parkinsons Dis. 10(S1):S57–S64.
2020.PubMed/NCBI View Article : Google Scholar
|
|
294
|
Chobanian AV, Volicer L, Tifft CP, Gavras
H, Liang CS and Faxon D: Mineralocorticoid-induced hypertension in
patients with Orthostatic Hypotension. N Engl J Med. 301:68–73.
1979.PubMed/NCBI View Article : Google Scholar
|
|
295
|
Grijalva CG, Biaggioni I, Griffin MR and
Shibao CA: Fludrocortisone is associated with a higher risk of
all-cause hospitalizations compared with midodrine in patients with
Orthostatic Hypotension. J Am Heart Assoc.
6(e006848)2017.PubMed/NCBI View Article : Google Scholar
|
|
296
|
Norcliffe-Kaufmann L, Axelrod FB and
Kaufmann H: Developmental abnormalities, blood pressure variability
and renal disease in Riley Day syndrome. J Hum Hypertens. 27:51–55.
2013.PubMed/NCBI View Article : Google Scholar
|
|
297
|
Campbell IW, Ewing DJ and Clarke BF:
9-Alpha-fluorohydrocortisone in the treatment of postural
hypotension in diabetic autonomic neuropathy. Diabetes. 24:381–384.
1975.PubMed/NCBI View Article : Google Scholar
|
|
298
|
Decaux G: Fludrocortisone in Orthostatic
Hypotension. N Engl J Med. 301:1121–1122. 1979.PubMed/NCBI
|
|
299
|
Van Lieshout JJ, Ten Harkel AD and Wieling
W: Fludrocortisone and sleeping in the head-up position limit the
postural decrease in cardiac output in autonomic failure. Clin
Auton Res. 10:35–42. 2000.PubMed/NCBI View Article : Google Scholar
|
|
300
|
Watt SJ, Tooke JE, Perkins CM and Lee MR:
The treatment of idiopathic Orthostatic Hypotension: A combined
fludrocortisone and flurbiprofen regime. Q J Med. 50:205–212.
1981.PubMed/NCBI
|
|
301
|
Low PA and Singer W: Management of
neurogenic orthostatic hypotension: An update. Lancet Neurol.
7:451–458. 2008.PubMed/NCBI View Article : Google Scholar
|
|
302
|
Low PA, Gilden JL, Freeman R, Sheng KN and
McElligott MA: Efficacy of midodrine vs placebo in neurogenic
orthostatic hypotension. A randomized, double-blind multicenter
study. Midodrine Study Group. JAMA. 277:1046–1051. 1997.PubMed/NCBI
|
|
303
|
Wright RA, Kaufmann HC, Perera R,
Opfer-Gehrking TL, McElligott MA, Sheng KN and Low PA: A
double-blind, dose-response study of midodrine in neurogenic
orthostatic hypotension. Neurology. 51:120–124. 1998.PubMed/NCBI View Article : Google Scholar
|
|
304
|
McTavish D and Goa KL: Midodrine. A review
of its pharmacological properties and therapeutic use in
orthostatic hypotension and secondary hypotensive disorders. Drugs.
38:757–777. 1989.PubMed/NCBI View Article : Google Scholar
|
|
305
|
Kaufmann H, Norcliffe-Kaufmann L and Palma
JA: Droxidopa in neurogenic orthostatic hypotension. Expert Rev
Cardiovasc Ther. 13:875–891. 2015.PubMed/NCBI View Article : Google Scholar
|
|
306
|
Goodman BP, Claassen D and Mehdirad A:
Adjusting droxidopa for neurogenic orthostatic hypotension in a
patient with Parkinson disease. Clin Auton Res. 27 (Suppl
1):S17–S19. 2017.PubMed/NCBI View Article : Google Scholar
|
|
307
|
Gupta F, Karabin B and Mehdirad A:
Titrating droxidopa to maximize symptomatic benefit in a patient
with Parkinson disease and neurogenic orthostatic hypotension. Clin
Auton Res. 27:S15–S16. 2017.PubMed/NCBI View Article : Google Scholar
|
|
308
|
Cheshire WP: Chemical pharmacotherapy for
the treatment of orthostatic hypotension. Expert Opin Pharmacother.
20:187–199. 2019.PubMed/NCBI View Article : Google Scholar
|
|
309
|
Okamoto LE, Shibao C, Gamboa A, Choi L,
Diedrich A, Raj SR, Black BK, Robertson D and Biaggioni I:
Synergistic effect of norepinephrine transporter blockade and α-2
antagonism on blood pressure in autonomic failure. Hypertension.
59:650–656. 2012.PubMed/NCBI View Article : Google Scholar
|
|
310
|
Ramirez CE, Okamoto LE, Arnold AC, Gamboa
A, Diedrich A, Choi L, Raj SR, Robertson D, Biaggioni I and Shibao
CA: Efficacy of atomoxetine versus midodrine for the treatment of
orthostatic hypotension in autonomic failure. Hypertension.
64:1235–1240. 2014.PubMed/NCBI View Article : Google Scholar
|
|
311
|
Shibao CA, Palma JA, Celedonio JE,
Martinez J, Kaufmann H and Biaggioni I: Predictors of the pressor
response to the norepinephrine transporter inhibitor, atomoxetine.
neurogenic orthostatic hypotension. Hypertension. 78:525–531.
2021.PubMed/NCBI View Article : Google Scholar
|
|
312
|
Kim JS, Ryu DW, Oh JH, Lee YH, Park SJ,
Jeon K, Lee JY, Ho SH, So J, Im JH and Lee KS: Cardiovascular
autonomic dysfunction in patients with drug-induced parkinsonism. J
Clin Neurol. 13:15–20. 2017.PubMed/NCBI View Article : Google Scholar
|
|
313
|
Singer W, Sandroni P, Opfer-Gehrking TL,
Suarez GA, Klein CM, Hines S, O'Brien PC, Slezak J and Low PA:
Pyridostigmine treatment trial in neurogenic orthostatic
hypotension. Arch Neurol. 63:513–518. 2006.PubMed/NCBI View Article : Google Scholar
|
|
314
|
Byun JI, Moon J, Kim DY, Shin H, Sunwoo
JS, Lim JA, Kim TJ, Lee WJ, Lee HS, Jun J, et al: Efficacy of
single or combined midodrine and pyridostigmine in orthostatic
hypotension. Neurology. 89:1078–1086. 2017.PubMed/NCBI View Article : Google Scholar
|
|
315
|
Eschlböck S, Wenning G and Fanciulli A:
Evidence-based treatment of neurogenic orthostatic hypotension and
related symptoms. J Neural Transm (Vienna). 124:1567–1605.
2017.PubMed/NCBI View Article : Google Scholar
|
|
316
|
Shibao C, Okamoto L and Biaggioni I:
Pharmacotherapy of autonomic failure. Pharmacol Ther. 134:279–286.
2012.PubMed/NCBI View Article : Google Scholar
|
|
317
|
Mazza A, Ravenni R, Antonini A, Casiglia
E, Rubello D and Pauletto P: Arterial hypertension, a tricky side
of Parkinson's disease: Physiopathology and therapeutic features.
Neurol Sci. 34:621–627. 2013.PubMed/NCBI View Article : Google Scholar
|
|
318
|
Zeng G and Quon MJ: Insulin-stimulated
production of nitric oxide is inhibited by wortmannin. Direct
measurement in vascular endothelial cells. J Clin Invest.
98:894–898. 1996.PubMed/NCBI View Article : Google Scholar
|
|
319
|
Okamoto LE, Celedonio JE, Smith EC, Gamboa
A, Shibao CA, Diedrich A, Paranjape SY, Black BK, Muldowney JAS
III, Peltier AC, et al: Local Passive Heat for the Treatment of
Hypertension in Autonomic Failure. J Am Heart Assoc.
10(e018979)2021.PubMed/NCBI View Article : Google Scholar
|
|
320
|
Okamoto LE, Celedonio JE, Smith EC,
Paranjape SY, Black BK, Wahba A, Park JW, Shibao CA, Diedrich A and
Biaggioni I: Continuous positive airway pressure for the treatment
of supine hypertension and orthostatic hypotension in autonomic
failure. Hypertension. 80:650–658. 2023.PubMed/NCBI View Article : Google Scholar
|
|
321
|
Arnold AC, Okamoto LE, Gamboa A, Black BK,
Raj SR, Elijovich F, Robertson D, Shibao CA and Biaggioni I:
Mineralocorticoid receptor activation contributes to the supine
hypertension of autonomic failure. Hypertension. 67:424–429.
2016.PubMed/NCBI View Article : Google Scholar
|
|
322
|
Jordan J, Fanciulli A, Tank J,
Calandra-Buonaura G, Cheshire WP, Cortelli P, Eschlboeck S, Grassi
G, Hilz MJ, Kaufmann H, et al: Management of supine hypertension in
patients with neurogenic orthostatic hypotension: Scientific
statement of the American Autonomic Society, European Federation of
Autonomic Societies, and the European Society of Hypertension. J
Hypertens. 37:1541–1546. 2019.PubMed/NCBI View Article : Google Scholar
|
|
323
|
Gomperts SN: Lewy body dementias: Dementia
with Lewy bodies and Parkinson disease dementia. Continuum (Minneap
Minn). 22 (2 Dementia):435–463. 2016.PubMed/NCBI View Article : Google Scholar
|
|
324
|
Walker Z, Possin KL, Boeve BF and Aarsland
D: Lewy body dementias. Lancet. 386:1683–1697. 2015.PubMed/NCBI View Article : Google Scholar
|
|
325
|
Goodnick PJ and Goldstein BJ: Selective
serotonin reuptake inhibitors in affective disorders-I. Basic
pharmacology. J Psychopharmacol. 12 (3 Suppl B):S5–S20.
1998.PubMed/NCBI View Article : Google Scholar
|
|
326
|
Owens MJ, Morgan WN, Plott SJ and Nemeroff
CB: Neurotransmitter receptor and transporter binding profile of
antidepressants and their metabolites. J Pharmacol Exp Ther.
283:1305–1322. 1997.PubMed/NCBI
|
|
327
|
Wagg A, Dale M, Tretter R, Stow B and
Compion G: Randomised, multicentre, placebo-controlled,
double-blind crossover study investigating the effect of
solifenacin and oxybutynin in elderly people with mild cognitive
impairment: the SENIOR study. Eur Urol. 64:74–81. 2013.PubMed/NCBI View Article : Google Scholar
|
|
328
|
Peroutka SJ and Snyder SH: Antiemetics:
Neurotransmitter receptor binding predicts therapeutic actions.
Lancet. 1:658–659. 1982.PubMed/NCBI View Article : Google Scholar
|
|
329
|
Wallace DM, Wohlgemuth WK, Trotti LM,
Amara AW, Malaty IA, Factor SA, Nallu S, Wittine L and Hauser RA:
Practical evaluation and management of insomnia in Parkinson's
Disease: A review. Mov Disord Clin Pract. 7:250–266.
2020.PubMed/NCBI View Article : Google Scholar
|
|
330
|
Orgeta V, McDonald KR, Poliakoff E, Hindle
JV, Clare L and Leroi I: Cognitive training interventions for
dementia and mild cognitive impairment in Parkinson's Disease.
Cochrane Database Syst Rev. 2(CD011961)2020.PubMed/NCBI View Article : Google Scholar
|
|
331
|
da Silva FC, Iop RDR, de Oliveira LC, Boll
AM, de Alvarenga JGS, Gutierres Filho PJB, de Melo LMAB, Xavier AJ
and da Silva R: Effects of physical exercise programs on cognitive
function in Parkinson's Disease patients: A systematic review of
randomized controlled trials of the last 10 years. PLoS One.
13(e0193113)2018.PubMed/NCBI View Article : Google Scholar
|
|
332
|
Picelli A, Varalta V, Melotti C, Zatezalo
V, Fonte C, Amato S, Saltuari L, Santamato A, Fiore P and Smania N:
Effects of treadmill training on cognitive and motor features of
patients with mild to moderate Parkinson's Disease: A pilot,
single-blind, randomized controlled trial. Funct Neurol. 31:25–31.
2016.PubMed/NCBI View Article : Google Scholar
|
|
333
|
Trung J, Hanganu A, Jobert S, Degroot C,
Mejia-Constain B, Kibreab M, Bruneau MA, Lafontaine AL, Strafella A
and Monchi O: Transcranial magnetic stimulation improves cognition
over time in Parkinson's Disease. Parkinsonism Relat Disord.
66:3–8. 2019.PubMed/NCBI View Article : Google Scholar
|
|
334
|
Doruk D, Gray Z, Bravo GL, Pascual-Leone A
and Fregni F: Effects of tDCS on executive function in Parkinson's
Disease. Neurosci Lett. 582:27–31. 2014.PubMed/NCBI View Article : Google Scholar
|
|
335
|
Manenti R, Cotelli MS, Cobelli C, Gobbi E,
Brambilla M, Rusich D, Alberici A, Padovani A, Borroni B and
Cotelli M: Transcranial direct current stimulation combined with
cognitive training for the treatment of Parkinson Disease: A
randomized, placebo-controlled study. Brain Stimulat. 11:1251–1262.
2018.PubMed/NCBI View Article : Google Scholar
|
|
336
|
Arendt T, Bigl V, Arendt A and Tennstedt
A: Loss of neurons in the nucleus basalis of Meynert in Alzheimer's
disease, paralysis agitans and Korsakoff's Disease. Acta
Neuropathol. 61:101–108. 1983.PubMed/NCBI View Article : Google Scholar
|
|
337
|
Kandiah N, Pai MC, Senanarong V, Looi I,
Ampil E, Park KW, Karanam AK and Christopher S: Rivastigmine: The
advantages of dual inhibition of acetylcholinesterase and
butyrylcholinesterase and its role in subcortical vascular dementia
and Parkinson's Disease dementia. Clin Interv Aging. 12:697–707.
2017.PubMed/NCBI View Article : Google Scholar
|
|
338
|
Devos D, Moreau C, Maltête D, Lefaucheur
R, Kreisler A, Eusebio A, Defer G, Ouk T, Azulay JP, Krystkowiak P,
et al: Rivastigmine in apathetic but dementia and depression-free
patients with Parkinson's Disease: A double-blind,
placebo-controlled, randomised clinical trial. J Neurol Neurosurg
Psychiatry. 85:668–674. 2014.PubMed/NCBI View Article : Google Scholar
|
|
339
|
Viramo P, Luukinen H, Koski K, Laippala P,
Sulkava R and Kivela SL: Orthostatic hypotension and cognitive
decline in older people. J Am Geriatr Soc. 47:600–604.
1999.PubMed/NCBI View Article : Google Scholar
|
|
340
|
Kuo HK, Sorond F, Iloputaife I, Gagno M,
Milberg W and Lipsitz LA: Effect of blood pressure on cognitive
functions in elderly persons. J Gerontol Biol Sci Med Sci.
59:1191–1194. 2004.PubMed/NCBI View Article : Google Scholar
|
|
341
|
Allcock LM, Kenny RA and Burn DJ: Clinical
phenotype of subjects with Parkinson's disease and orthostatic
hypotension: Autonomic symptom and demographic comparison. Mov
Disord. 21:1851–1855. 2006.PubMed/NCBI View Article : Google Scholar
|
|
342
|
Yap PL, Niti M, Yap KB and Ng TP:
Orthostatic hypotension, hypotension and cognitive status: Early
comorbid markers of primary dementia? Dement Geriatr Cogn Disord.
26:239–246. 2008.PubMed/NCBI View Article : Google Scholar
|
|
343
|
Bendini C, Angelini A, Salsi F, Finelli
ME, Martini E, Neviani F, Mussi C and Neri M: Relation of
neurocardiovascular instability to cognitive, emotional and
functional domains. Arch Gerontol Geriatr. 44 (Suppl 1):S69–S74.
2007.PubMed/NCBI View Article : Google Scholar
|
|
344
|
Rose KM, Couper D, Eigenbrodt ML, Mosley
TH, Sharrett AR and Gottesman RF: Orthostatic hypotension and
cognitive function: The Atherosclerosis Risk in Communities Study.
Neuroepidemiology. 34:1–7. 2010.PubMed/NCBI View Article : Google Scholar
|
|
345
|
Hauser RA, Heritier S, Rowse GJ, Hewitt LA
and Isaacson SH: Droxidopa and reduced falls in a trial of
Parkinson disease patients with neurogenic orthostatic hypotension.
Clin Neuropharmacol. 39:220–226. 2016.PubMed/NCBI View Article : Google Scholar
|
|
346
|
Brignole M, Moya A, de Lange FJ, Deharo
JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA,
Martín A, et al: 2018 ESC Guidelines for the diagnosis and
management of syncope. Eur Heart J. 39:1883–1948. 2018.PubMed/NCBI View Article : Google Scholar
|
|
347
|
Shannon J, Jordan J, Costa F, Robertson RM
and Biaggioni I: The hypertension of autonomic failure and its
treatment. Hypertension. 30:1062–1067. 1997.PubMed/NCBI View Article : Google Scholar
|
|
348
|
Arnold AC, Okamoto LE, Gamboa A, Shibao C,
Raj SR, Robertson D and Biaggioni I: Angiotensin II, independent of
plasma renin activity, contributes to the hypertension of autonomic
failure. Hypertension. 61:701–706. 2013.PubMed/NCBI View Article : Google Scholar
|
|
349
|
Jordan J, Shannon JR, Pohar B, Paranjape
SY, Robertson D, Robertson RM and Biaggioni I: Contrasting effects
of vasodilators on blood pressure and sodium balance in the
hypertension of autonomic failure. J Am Soc Nephrol. 10:35–42.
1999.PubMed/NCBI View Article : Google Scholar
|
|
350
|
Dubois B, Tolosa E, Katzenschlager R, Emre
M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, et
al: Donepezil in Parkinson's disease dementia: A randomized,
double-blind efficacy and safety study. Mov Disord. 27:1230–1238.
2012.PubMed/NCBI View Article : Google Scholar
|
|
351
|
Wang HF, Yu JT, Tang SW, Jiang T, Tan CC,
Meng XF, Wang C, Tan MS and Tan L: Efficacy and safety of
cholinesterase inhibitors and memantine in cognitive impairment in
Parkinson's disease, Parkinson's disease dementia, and dementia
with Lewy bodies: Systematic review with meta-analysis and trial
sequential analysis. J Neurol Neurosurg Psychiatry. 86:135–143.
2015.PubMed/NCBI View Article : Google Scholar
|
|
352
|
Litvan I, Goldman JG, Troster AI, Schmand
BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K,
Williams-Gray CH, et al: Diagnostic criteria for mild cognitive
impairment in Parkinson's disease: Movement disorder society task
force guidelines. Mov Disord. 27:349–356. 2012.PubMed/NCBI View Article : Google Scholar
|
|
353
|
Emre M, Tsolaki M, Bonuccelli U, Destee A,
Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladström
A and Jones R: 11018 Study Investigators. Memantine for patients
with Parkinson's disease dementia or dementia with Lewy bodies: A
randomised, double-blind, placebo-controlled trial. Lancet Neuro.
9:969–977. 2010.PubMed/NCBI View Article : Google Scholar
|
